Creative Planning Sells 7,534 Shares of TG Therapeutics, Inc. $TGTX

Creative Planning lessened its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 8.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 80,753 shares of the biopharmaceutical company’s stock after selling 7,534 shares during the quarter. Creative Planning owned approximately 0.05% of TG Therapeutics worth $2,906,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Ameritas Advisory Services LLC bought a new position in shares of TG Therapeutics during the 2nd quarter valued at about $25,000. SVB Wealth LLC purchased a new stake in shares of TG Therapeutics in the first quarter worth about $37,000. Private Wealth Asset Management LLC bought a new position in TG Therapeutics during the second quarter valued at approximately $37,000. Brooklyn Investment Group boosted its stake in TG Therapeutics by 2,159.2% during the first quarter. Brooklyn Investment Group now owns 1,604 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 1,533 shares during the last quarter. Finally, CWM LLC grew its holdings in TG Therapeutics by 16.2% during the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 290 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Trading Up 4.9%

Shares of TGTX opened at $31.95 on Monday. The company’s fifty day simple moving average is $33.78 and its 200-day simple moving average is $33.94. The company has a market cap of $5.07 billion, a P/E ratio of 86.35 and a beta of 1.95. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. TG Therapeutics, Inc. has a twelve month low of $25.28 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $2.19. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The firm had revenue of $161.71 million during the quarter, compared to analysts’ expectations of $152.12 million. During the same period in the previous year, the company earned $0.02 EPS. The firm’s revenue for the quarter was up 92.7% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of the stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the sale, the director directly owned 94,061 shares in the company, valued at approximately $3,032,526.64. This represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 10.64% of the company’s stock.

Wall Street Analyst Weigh In

TGTX has been the topic of several recent research reports. B. Riley raised TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research note on Wednesday. HC Wainwright assumed coverage on shares of TG Therapeutics in a research note on Monday, October 6th. They issued a “buy” rating and a $60.00 price objective for the company. Wall Street Zen upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, JPMorgan Chase & Co. increased their price target on shares of TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $50.25.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.